cbd news 2021December 15, 2021
The global cannabidiol market size is anticipated to expand at substantial CAGR during the forecast period as CBD is quite famous for treating large number of ailments like anxiety, chronic and neurological pains, sleep disorders, stress, and nausea.
There are several applications of CBD like anxiety, chronic stress, depression, skin care, seizures, joint pain & inflammations, among others. Out of these, CBD will find increased application in the chronic pain segment through 2027, reaching a valuation of $20.6 billion by 2027 across North America, according to current market trends. CBD has several beneficial properties to relieve chronic pain and is a better alternative when compared to its counterpart, opioids.
Access sample pages of the report, “ Europe Cannabidiol (CBD) Market Forecasts 2027 ” in detail along with the table of contents (ToC) @
Prominent CBD manufacturers across the globe include Canopy Growth Corporation, Cronos Group, Medterra Tilray, CBD One Ltd, Formula Swiss AG, Green Brothers Switzerland SA, HemPoland sp. z o.o. MH medical hemp GmbH, ECOFIBRE, Bod Australia Ltd, MEDLAB CLINICAL, Aurora Cannabis, and CV Sciences, Inc.
Chronic pain patients are the largest consumers of CBD in U.S.:
In fact, this segment dominated the market in 2019 and will continue to do so in the future as well. CBD oil is known to have several benefits for its users, especially for pain-related ailments. Cases of mental illness in North America are increasing every year. Mental health institutions are increasingly demanding CBD oil as it is quite famous for treating various mental illnesses like depression and anxiety, thereby positively influencing the substance demand.
Anxiety, chronic stress, depression, migraines, skincare, inflammation, and many other areas are using CBD-based products for various purposes. But it is the anxiety & stress segment that will attract the most demand for this product in the coming years. This segment captured 22% of the total Europe market share in 2020 and is expected to grow further in the future.
Cannabidiol oil will witness hike in demand in North America:
Access sample pages of the report, “ Asia Pacific Cannabidiol (CBD) Market Forecasts 2027 ” in detail along with the table of contents (ToC) @
CBD market in Asia Pacific is predicted to become worth more than $1.9 billion by 2027, according to market reports. CBD was not on the list of legal products in several countries across the region. But today, that scenario has drastically changed as countries like Japan, Australia and New Zealand have made favorable changes in their laws to make the use of CBD based products legal among their population.
The regulatory bodies of these countries have inspected the benefits of CBD-derived products on human body and have given their approval in this regard. For example, Australian authorities approved the use of a CBD-based product, Sativex in 2017 to treat spasticity caused by multiple sclerosis. This drug has won the approval of more than 28 countries, which is an indication of positive changes in the regulatory framework of these nations. All these factors will positively impact the demand for CBD in Asia Pacific.
About Graphical Research:
North America cannabidiol market is expected to surpass $61.2 billion in size by 2027. Based on product, this market is divided into oil, tinctures, transdermal patches, suppository, tablets, capsules, vape oil, isolates, creams, roll-ons, and many others. Out of these, the CBD oil segment is projected to grow rapidly during the forecast period of 2021-2027.
Creams and roll-ons will experience increased demand in Europe:
CBD gives minimal side-effects from use and does not contain toxic elements. This has resulted in increased demand for CBD-derived medicines and products as a better alternative to conventional medicines, augmenting the market size in the U.S.
There are two primary distribution channels established to sell CBD in North America: online and offline channels. The offline distribution channels are further divided into pharmacies and retail stores. The offline distribution channel in the region is set to gain momentum through 2027 and will expand at 32.6% CAGR during this time.
Favorable government regulations to foster Asia Pacific cannabidiol market:
Pune, India, June 02, 2021 (GLOBE NEWSWIRE) —
Total Europe CBD market is projected to go past $25.8 billion by 2027. Oils, tablets, creams & roll-ons, capsules, vape oil and many other products use CBD oil as the main ingredient. Out of these, the creams & roll-ons segment will witness robust growth during the mentioned timeline as there is a rising emphasis among consumers to use skincare products that contain CBD.
Tyler Marshall, University of Alberta and Jonathan N. Stea, University of Calgary.
Associate Professor of Urban/Regional Planning, The University of Western Australia.
Distinguished Professor and Head of the Department of Pharmacy Practice, University of Connecticut.
CBD sales are soaring, but evidence is still slim that the cannabis derivative makes a difference for anxiety or pain.
Post-doctoral researcher, UCL.
Michelle Ward, L’Université d’Ottawa/University of Ottawa.
Director, Southern Cross Plant Science, Southern Cross University.
Amie Hayley, Swinburne University of Technology.
Gary Mortimer, Queensland University of Technology ; Louise Grimmer, University of Tasmania , and Paul J. Maginn, The University of Western Australia.
Professor of Marketing and Consumer Behaviour, Queensland University of Technology.
How COVID all but killed the Australian CBD.
Senior Lecturer in Retail Marketing, University of Tasmania.
Senior Lecturer in Urban Planning & Design, Monash University.
Associate Professor of Addiction, University of York.
Brandon McFadden, University of Delaware and Trey Malone, Michigan State University.
Pediatricians seeing a growing demand for medical cannabis for kids.
Professor of Pharmacy Practice, Drake University.
Paul J. Maginn, The University of Western Australia and Gary Mortimer, Queensland University of Technology.
Professor of Architecture and Urban Design, The University of Melbourne.
Stephanie Lake, University of British Columbia and M-J Milloy, University of British Columbia.
Honorary Professional Fellow, Faculty of Design, Architecture and Building, University of Technology Sydney.
Despite being federally legal, I’ve observed that CBD companies still have problems obtaining capital and standard services from banks and other financial services institutions. And the ability to market CBD as a safe and effective substance is limited by how the FDA classifies it.
3. Big-box retail access will spur sales while stabilizing and improving supply chains.
This new distribution could vastly grow the market while benefiting various supply chain components, including hemp farmers and labs that conduct the extraction, distillation, crystallization and isolation of CBD from plants. A particular benefit will be incentivizing more quality labs to get in the CBD game, as many facilities now hesitate to stray from their core competencies. The price of raw materials will also drastically increase as retail demand grows.
Best Travel Insurance Companies.
As the owner of a CBD company, I am in wait-and-see mode like many of my colleagues. We simply steer through these challenges to grow our companies. But I believe that lawmakers will solidify the status of CBD soon, removing barriers to innovation, safety and, ultimately, the normalization of the industry. When that happens, even more growth — exponential growth — is on the horizon.
CBD companies currently offer a pretty wide range of products. Nevertheless, this diversity will increase as more companies introduce products that hyper-concentrate on each of the over 100 minor cannabinoids found in the hemp plant. Formulations focusing on cannabinol (CBN), cannabigerol (CBG) and other compounds and mixes will be developed for specific use cases.
The crucial developments that will remove these barriers are the FDA classifying CBD as a dietary supplement, the industry’s unrestricted access to financial services and an intelligent regulatory framework that increases product quality and safety across the board.
CBD companies are tasked with seizing this opportunity while navigating the significant hurdles. As a founder and owner, here is my take on the crucial developing issues in my industry, along with predictions about what will happen.
1. CBD has become big business, and it’s set to get much bigger and more diverse.
In addition, more precise federal regulation of product quality will be a rising tide that lifts most boats, as bad players drop off in survival-of-the-fittest fashion.
Best Covid-19 Travel Insurance Plans.
In some ways, the CBD industry is an unstoppable juggernaut. It’s already a multi-billion-dollar sector that will only get bigger, as millions of consumers have made their preferences clear. But CBD companies still have to navigate many unique hurdles, from obtaining capital to using standard payment processing to being able to market on regular channels.
Many CBD companies, which now mainly self-regulate, will be forced to improve their quality assurance and compliance efforts to survive. And the providers who already sell high-caliber products will finally reap the rewards of their investments in R&D and production that have necessarily reduced ROI.
Once companies can market CBD as a dietary supplement, it’s my opinion that it will hit the mainstream of brick-and-mortar retail. In particular, big-box chains will offer a range of topicals and ingestibles in various product categories and applications.
Every industry has its challenges and opportunities, but I believe the CBD industry is in a unique — and pivotal — position. As a substance that was federally illegal before the passage of the 2018 Farm Bill, hemp-derived cannabinoids with no more than 0.3% THC still face a regulatory grey area. This ambiguity creates a host of novel challenges in financing, marketing and producing products. But simultaneously, the industry and market are growing incredibly fast.
4. More big names will get into the game through acquisitions.
CBD sales in the U.S. hit $4.6 billion in 2020, a massive number just two years after hemp-derived cannabinoids were federally legalized. This growth is only expected to accelerate, with two notable forecasts projecting a U.S. market of $15 billion to more than $20 billion by 2025 and 2024, respectively.
The future of CBD is bright, but it still hinges on crucial developments.
2. Regulatory challenges remain, and it will take Congress to clarify things.
An all-time high in public education about cannabinoids will accompany the mainstreaming of CBD. Through this, consumers will be able to feel more confident and safer while purchasing products that are smartly regulated.